These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 34463983)

  • 41. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involvement of a periodontal pathogen, Porphyromonas gingivalis on the pathogenesis of non-alcoholic fatty liver disease.
    Yoneda M; Naka S; Nakano K; Wada K; Endo H; Mawatari H; Imajo K; Nomura R; Hokamura K; Ono M; Murata S; Tohnai I; Sumida Y; Shima T; Kuboniwa M; Umemura K; Kamisaki Y; Amano A; Okanoue T; Ooshima T; Nakajima A
    BMC Gastroenterol; 2012 Feb; 12():16. PubMed ID: 22340817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
    Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.
    Lim S; Taskinen MR; Borén J
    Obes Rev; 2019 Apr; 20(4):599-611. PubMed ID: 30589487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
    Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
    Dowman JK; Hopkins LJ; Reynolds GM; Nikolaou N; Armstrong MJ; Shaw JC; Houlihan DD; Lalor PF; Tomlinson JW; Hübscher SG; Newsome PN
    Am J Pathol; 2014 May; 184(5):1550-61. PubMed ID: 24650559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The common marmoset as a model for the study of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kramer JA; Grindley J; Crowell AM; Makaron L; Kohli R; Kirby M; Mansfield KG; Wachtman LM
    Vet Pathol; 2015 Mar; 52(2):404-13. PubMed ID: 24913270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms and disease consequences of nonalcoholic fatty liver disease.
    Loomba R; Friedman SL; Shulman GI
    Cell; 2021 May; 184(10):2537-2564. PubMed ID: 33989548
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-inflammatory activities of green tea catechins along the gut-liver axis in nonalcoholic fatty liver disease: lessons learned from preclinical and human studies.
    Hodges JK; Sasaki GY; Bruno RS
    J Nutr Biochem; 2020 Nov; 85():108478. PubMed ID: 32801031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
    Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
    Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter.
    Cha JY; Park JM; Lee HJ; Bae JS; Han YM; Oh BC; Ko KH; Hahm KB
    Curr Pharm Des; 2017; 23(27):3941-3951. PubMed ID: 28714405
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial.
    Kamata Y; Kessoku T; Shimizu T; Kobayashi T; Kurihashi T; Sato S; Kuraji S; Aoyama N; Iwasaki T; Takashiba S; Hamada N; Kodama T; Tamura T; Ino S; Higurashi T; Taguri M; Yamanaka T; Yoneda M; Usuda H; Wada K; Nakajima A; Minabe M
    Trials; 2020 Mar; 21(1):291. PubMed ID: 32293522
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis.
    Albuquerque-Souza E; Sahingur SE
    Periodontol 2000; 2022 Jun; 89(1):125-141. PubMed ID: 35244954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.